Dutch website Oncologie.nu has interviewed CiMaas’ Gerard Bos on the development of the dendritic cell vaccine for lung cancer.
In an interview, published in the Dutch language Gerard Bos describes the inventions made at the Maastricht University, the start-up of CiMaas to bring these inventions to the clinic, the development of a production method and clinical protocols that will lead to first-in-human trials delivering in house manufactured Dendritic cell vaccines to lung cancer patients receiving checkpoint inhibitors.
checkpoint inhibitor, dendritic cell vaccine, interview, lung cancer